AMA Honors Government Service, Dedication to Health Care
26th anniversary of the Dr. Nathan Davis Awards for Outstanding Government Service
WASHINGTON -- The American Medical Association (AMA) today announced the seven recipients of the 2015 Dr. Nathan Davis Award for Outstanding Government Service – the highest award for elected officials and government employees from the nation's largest physician organization.
The award, named for the founding father of the AMA, recognizes elected and career officials in federal, state or municipal service whose outstanding contributions have promoted the art and science of medicine and the betterment of public health. This year's recipients include:
United States Representative
Governor, Elected Statewide Official
Member of Executive Branch in Career Public Service
- Bruce G. Gellin, M.D., M.P.H., Deputy Assistant Secretary for Health and Director, National Vaccine Program Office
- Dale P. Sandler, Ph.D., Principal Investigator and Chief of Epidemiology, National Institutes of Health, National Institute of Environmental Health Sciences
Member of a State Legislature
Career Public Servant at the State and Local Level
During the past 26 years, the AMA has honored more than 200 men and women with the Nathan Davis Award.
'The AMA's Nathan Davis Awards recognize government officials who go above and beyond the call of duty to support our nation's health,' said AMA Chair Barbara L. McAneny, M.D. 'Award winners have come from every branch of government service and are a testament to the important role that policymakers play in improving the health of our nation.'
The awards were presented tonight in conjunction with the AMA National Advocacy Conference in Washington D.C.
-
Most popular related searches
Related news
-
SeqOne Genomics closes €20M series A to accelerate the deployment of its genomic medicine platform
The round, led by Omnes, Merieux Equity Partners, together with the Software Club and existing investors, Elaia and IRDI Capital Investissement, will enable SeqOne Genomics to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, in order to improve patient outcomes in cancer and hereditary disease. The company will intensify investments in the development of its genomic-aware data lake to...
-
Daxor Corporation to Commence Trading on the Nasdaq Capital Market
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq Capital Market effective at the opening of trading on February 2, 2022, transferring the listing of its common stock from the New York Stock Exchange – American. Daxor’s common stock will continue trading under the ticker symbol “DXR” after the transfer. The Company’s common stock will continue to trade on the NYSE American until the...
-
The Indoor Microbiome and Its Impact on Indoor Environmental Quality
Last year, the U.S. Environmental Protection Agency (EPA) announced the release of a new webpage to provide information about the indoor microbiome. All of the living microorganisms inside of an indoor environment, and their by-products, are collectively known as the indoor microbiome. The indoor microbiome that surrounds each of us is diverse and dynamic, made up of bacteria, viruses, fungi and other single-celled organisms. These microorganisms may be growing or inactive, and may be present in different life...
-
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022. Mr. Feldshuh will provide company updates and key highlights, including a new patent award and progress with BVA-100® next generation development. The presentation will be available on-demand beginning at 7:00 a.m. ET...
-
Daxor Announces Key Milestones Achieved for Multicenter BVA-100 Study in Hospitalized Patients With COVID-19
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology in hospitalized COVID-19 patients. NYU Langone Health, Wake Forest School of Medicine and OHSU have been enrolling subjects since the onset of the pandemic. Dr. Jan Bakker, MD,...
Customer comments
No comments were found for AMA Honors Government Service, Dedication to Health Care. Be the first to comment!